Cardiovascular diseases research group (BIO-HEART)

Summary

This group focusses on clinical research in the area of cardiovascular diseases and risks, and has extensive experience in a highly relevant field, as cardiovascular diseases remain the main cause of mortality among both women and men in the Western world.
The group studies new surgical and pharmacological treatments for improving survival and recovery of patients affected by these diseases. It has extensive experience in the study of drugs which prevent platelet aggregation in the blood, specifically.

2089

Publications

Strategic lines

Selected Publications

Collado Lledó,E;de la Cuerda,F;Ariza Solé,A, Sex Differences in Acute Heart Failure Management: Is There a Gap in Treatment Quality?, Curr. Heart Fail. Rep., 2023;20(2):121-128, doi:10.1007/s11897-023-00593-2
Francia,P;Viveros,D;Falasconi,G;Penela,D;Soto Iglesias,D;Martí Almor,J;Alderete,J et al, Clinical impact of aging on outcomes of cardioneuroablation for reflex syncope or functional bradycardia: Results from the cardionEuroabLation: patiEnt selection, imaGe integrAtioN and outComEs-The ELEGANCE multicenter study)., Heart Rhythm, 2023;20(9):1279-1286, doi:10.1016/j.hrthm.2023.06.007
Bonaca,MP;Lesén,E;Giannitsis,E;Hedberg,J;Jernberg,T;Lambrelli,D;Duong,M et al, Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study, EUR. HEART J.-CARDIOVASC. PHARMACOTHER., 2023;9(8):701-708, doi:10.1093/ehjcvp/pvad062
Herrera Hidalgo,L;Muñoz,P;Álvarez Uría,A;Alonso Menchén,D;Luque Marquez,R;Gutiérrez Carretero,E;Fariñas,MDC et al, Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort., Int. J. Infect. Dis., 2023;137134-143, doi:10.1016/j.ijid.2023.10.019
Vicent,L;Alvarez Garcia,J;Vazquez Garcia,R;Gonzalez Juanatey,JR;Rivera,M;Segovia,J;Pascual Figal,D et al, Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction, J. Clin. Med., 2023;12(8):doi:10.3390/jcm12083028

Selected Projects

MCI21056. Estrategias preventivas integradoras para el cáncer y las enfermedades cardiovasculares basadas en inteligencia artificial (IA). Ministerio de Ciencia e Innovación. Budget: 569.250€. 2022-2024. PI: COMÍN COLET, JOSEP.
FORT23/00032_4. Smart Health Community (SHC), promoviendo la medicina basada en el valor. Instituto de Salud Carlos III (ISCIII)/Fortalece. Budget: 416.724€. 2024-2027. PI: COMÍN COLET, JOSEP.
2022-109-1. ESTUDIO DE EXTENSIÓN ABIERTO DE FASE 3 PARA EVALUAR LA EFICACIA Y LA SEGURIDAD A LARGO PLAZO DE LIB003 EN PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HOMOCIGÓTICA Y HETEROCIGÓTICA, ENFERMEDAD CARDIOVASCULAR O ALTO RIESGO DE ENFERMEDAD CARDIOVASCULAR, EN TRATAMIENTO HIPOLIPEMIANTE ESTABLE QUE PRECISAN UNA REDUCCIÓN ADICIONAL DEL COLESTEROL UNIDO A LAS LIPOPROTEÍNAS DE BAJA DENSIDAD (LIBerate-OLE). MEDPACE CLINICAL RESEARCH, LLC. Budget: 401.128€. 2022- . PI: PINTO SALA, JAVIER.
20ACL119. HELIOS-B: ESTUDIO DE FASE 3, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE VUTRISIRÁN EN PACIENTES CON AMILOIDOSIS CARDIACA POR TRANSTIRETINA (AMILOIDOSIS POR ATTR CON MIOCARDIOPATÍA). ALNYLAM PHARMACEUTICALS, INC . Budget: 299.745€. 2020- . PI: González Costello, José.
MCI22001. Clinical trial to evaluate the administration of ApTOLL in Acute Myocardial Infarction. APSTEMI. Ministerio de Ciencia e Innovación. Budget: 259.100,89€. 2022-2025. PI: Gómez Hospital, Joan Antoni.